Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IQWIG

- PMLiVE

NICE backs new use for Bayer’s Eylea

Will go up against Novartis’ Lucentis in treatment of macular oedema in UK

- PMLiVE

Biosimilars: friend or foe for healthcare systems?

An opportunity in Europe, but widespread acceptance and uptake is by no means a done deal

- PMLiVE

Value-based assessment

NICE is set to modify the way it operates, but the changes shouldn’t come as a surprise

National Institute for Health and Care Excellence NICE logo

Janssen launches diabetes drug Invokana in UK

Launch coincides with draft NICE recommendation for the SGLT2 inhibitor

Biogen Idec building

NICE turns down Biogen Idec’s oral MS drug

UK HTA body says Tecfidera is not a cost-effective use of NHS resources

Define the patient burden in rare diseases

Putting patients and carers at the heart of the value demonstration equation in orphan drugs is key

- PMLiVE

EMA to expand orphan drug HTA collaboration

Will further develop the concept of parallel scientific advice in 2014

National Institute for Health and Care Excellence NICE logo

NICE calls for greater statin prescribing in wake of Lipitor generics

Wants more use of the drugs to help prevent cardiovascular disease

- PMLiVE

Germany looks again at Fycompa pricing

Eisai's epilepsy drug could be re-entered onto market

National Institute for Health and Care Excellence NICE logo

NICE reviews lung cancer drug guidance

Consults on availability of Roche's Tarceva and AZ's Iressa on NHS

- PMLiVE

EU gives boost to its network of HTA bodies

EUnetHTA strengthens role in market access in EU

- PMLiVE

NICE backs Astellas’ Xtandi in prostate cancer

But company criticises restrictions imposed by HTA body for England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links